BIRC5 and melanoma: Considering that the DCs used were injected intratumorally with the aim of in situ taking up antigen of DTIC-induced apoptotic tumor cells, we decided to test reactivity of T cells against a broad range of well-known melanoma associated antigens (i.e., MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, gp100, tyrosinase and survivin).